Graft versus host disease prophylaxis today.
Martelli
M F
MF
Institute of Haematology, University of Perugia, Italy.
Aversa
F
F
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000379:methods; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D006084:Graft Rejection; D006086:Graft vs Host Disease / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007938:Leukemia / Q000601:surgery; D008212:Lymphocyte Depletion; D051379:Mice; D009364:Neoplasm Recurrence, Local / Q000209:etiology; D013601:T-Lymphocytes / Q000276:immunology; D013852:Thiotepa / Q000009:adverse effects / Q000627:therapeutic use; D014916:Whole-Body Irradiation / Q000009:adverse effects
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D003520:Cyclophosphamide; D013852:Thiotepa